Abstract
Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Current Alzheimer Research
Title: Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Volume: 6 Issue: 6
Author(s): Orjan Hallberg
Affiliation:
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Abstract: Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Export Options
About this article
Cite this article as:
Hallberg Orjan, Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?, Current Alzheimer Research 2009; 6 (6) . https://dx.doi.org/10.2174/156720509790147098
DOI https://dx.doi.org/10.2174/156720509790147098 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science An Approach to Treatment of Liver Cancer by Novel Glycyrrhizin Derivative
Anti-Cancer Agents in Medicinal Chemistry P2X Receptors and Inflammation
Current Medicinal Chemistry Natural Products as a Source for Antileishmanial and Antitrypanosomal Agents
Combinatorial Chemistry & High Throughput Screening Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines
Letters in Organic Chemistry A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
Current Medicinal Chemistry Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor α/βDual Agonists for the Treatment of Type 2 Diabetes
Letters in Drug Design & Discovery Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Recent Developments of Small Molecule EGFR Inhibitors Based on the Quinazoline Core Scaffolds
Anti-Cancer Agents in Medicinal Chemistry The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Mitochondrial Effects of Organoselenium and Organotellurium Compounds
Current Organic Chemistry Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science A Novel Nanoformulation of Ellagic Acid is Promising in Restoring Oxidative Homeostasis in Rat Brains with Alzheimer’s Disease
Current Drug Metabolism Alternative Medicine Safety: Agaricus blazei and Propolis
Combinatorial Chemistry & High Throughput Screening Hyperpolarized <sup>13</sup>C MR Angiography
Current Pharmaceutical Design Recent Advances in the Development of Nonpeptide Somatostatin Receptor Ligands
Mini-Reviews in Medicinal Chemistry Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology